Subtype
Malignant Hepatobiliary Neoplasm
CI-CAN-00001136Explore in graph →
1,160 active trials17 approved drugs42 evidence items
- NCIt
- C8609
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001136Explore in graph →
Clinical trials
5,029 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (561)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03897543 | ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 10 | Abivax S.A.INDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07845266 | Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GKL-006 Injection in Combination With TACE in Unresectable Hepatocellular Carcinoma | completed | Phase 1 | 13 | Beijing Gene Key Life Technology Co., LtdINDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT05858736 | Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors(PRESERVE-009) | completed | Phase 1 | 18 | OncoC4, Inc.INDUSTRY | 1 | Sep 14, 2026 | clinicaltrials |
| NCT03674073 | A Study Combining Personalized Neoantigen-based Dendritic Cell Vaccine With Microwave Ablation for the Treatment of Hepatocellular Carcinoma | completed | Phase 1 | 24 | Chinese PLA General HospitalOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT05220046 | Palliadelic Treatment to Reduce Psychological Distress in Persons With Advanced Gastrointestinal Cancers | completed | Phase 1 | 18 | University of NebraskaOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT04374877 | Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors | completed | Phase 1 | 145 | Coherus Oncology, Inc.INDUSTRY | 3 | Jul 15, 2026 | clinicaltrials |
| NCT03682276 | Safety and Bioactivity of Ipilimumab and Nivolumab Combination Prior to Liver Resection in Hepatocellular Carcinoma(PRIME-HCC) | completed | Phase 1 / Phase 2 | 33 | Imperial College LondonOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT05742750 | A Phase Ib/II Clinical Study of Camrelizumab and Apatinib Plus GP in the Treatment of Advanced Biliary Tract Cancer(HP-BTC-001) | completed | Phase 1 / Phase 2 | 49 | Sun Yat-sen UniversityOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT03132792 | AFPᶜ³³²T in Advanced HCC | completed | Phase 1 | 39 | AdaptimmuneINDUSTRY | 4 | Jun 17, 2026 | clinicaltrials |
| NCT05773105 | A Study of Cadonilimab Combined With Regorafenib in Patients With Advanced HCC | completed | Phase 1 / Phase 2 | 36 | Sun Yat-sen UniversityOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT05964361 | First-in-human Interleukin-15-transpresenting Wilms' Tumor Protein 1-targeting Autologous Dendritic Cell Vaccination in Cancer Patients(IL15-TransDC) | completed | Phase 1 / Phase 2 | 10 | University Hospital, AntwerpOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT03552718 | QUILT-2.025 NANT Neoepitope Yeast Vaccine (YE-NEO-001): Adjuvant Immunotherapy Using a Personalized Neoepitope Yeast-Based Vaccine To Induce T-Cell Responses In Subjects W/ Previously Treated Cancers. | completed | Phase 1 | 5 | NantBioScience, Inc.INDUSTRY | 1 | May 7, 2026 | clinicaltrials |
| NCT04358185 | Itacitinib in Advanced Hepatocellular Carcinoma(JAKaL) | completed | Phase 1 | 19 | Imperial College LondonOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT05411133 | Treatment of Cabotamig (ARB202) in Advanced Gastrointestinal Cancer Patients | completed | Phase 1 | 33 | Arbele Pty LtdINDUSTRY | 2 | Mar 19, 2026 | clinicaltrials |
| NCT06354387 | Alectinib in Combination With Nivolumab in the Treatment of Recurrent or Refractory HCC Patients Guided With Serum RNase1 and Tumor Expression of PD-L1 | completed | Phase 1 | 5 | China Medical University HospitalOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT04526106 | REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 490 | Elevar TherapeuticsINDUSTRY | 13 | Feb 27, 2026 | clinicaltrials |
| NCT02073994 | Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation | completed | Phase 1 | 174 | Institut de Recherches Internationales ServierOTHER | 2 | Feb 17, 2026 | clinicaltrials |
| NCT04418401 | Study on the Safety and Efficacy of Donafinib Combined With Anti-PD-1 Antibody as Adjuvant Therapy for HCC Patients(CISLD-8) | completed | Phase 1 | 30 | Zhejiang UniversityOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT03785873 | Phase Ib/II Trial of Nal-Irinotecan and Nivolumab as Second-Line Treatment in Patients With Advanced Biliary Tract Cancer | completed | Phase 1 / Phase 2 | 34 | University of Michigan Rogel Cancer CenterOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT03211416 | Sorafenib Tosylate and Pembrolizumab in Treating Patients With Advanced or Metastatic Liver Cancer | completed | Phase 1 / Phase 2 | 37 | Roswell Park Cancer InstituteOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT06310590 | Safety and Efficacy of TareSphere in Patients With Unresectable Hepatocellular Carcinoma | completed | Phase 1 | 40 | Chengdu New Radiomedicine Technology Co. LTD.INDUSTRY | 1 | Feb 3, 2026 | clinicaltrials |
| NCT05337137 | A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver Cancer(RELATIVITY-106) | completed | Phase 1 / Phase 2 | 83 | Bristol-Myers SquibbINDUSTRY | 15 | Jan 12, 2026 | clinicaltrials |
| NCT01658878 | An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer(CheckMate040) | completed | Phase 1 / Phase 2 | 657 | Bristol-Myers SquibbINDUSTRY | 13 | Dec 24, 2025 | clinicaltrials |
| NCT05091346 | A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors | completed | Phase 1 / Phase 2 | 89 | Eisai Inc.INDUSTRY | 4 | Oct 24, 2025 | clinicaltrials |
| NCT02159989 | Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery | completed | Phase 1 | 83 | National Cancer Institute (NCI)NIH | 1 | Oct 20, 2025 | clinicaltrials |
| NCT05293496 | A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors | completed | Phase 1 | 31 | MacroGenicsINDUSTRY | 1 | Oct 14, 2025 | clinicaltrials |
| NCT05052099 | Phase Ib/II Single-arm Study of mFOLFOX6, Bevacizumab and Atezolizumab in Advanced Biliary Tract Cancer(COMBATBIL) | completed | Phase 1 / Phase 2 | 20 | University Hospital, EssenOTHER | 2 | Sep 29, 2025 | clinicaltrials |
| NCT04853017 | A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors(AMPLIFY-201) | completed | Phase 1 | 25 | Elicio TherapeuticsINDUSTRY | 1 | Sep 5, 2025 | clinicaltrials |
| NCT03314935 | A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors | completed | Phase 1 / Phase 2 | 149 | Incyte CorporationINDUSTRY | 3 | Aug 12, 2025 | clinicaltrials |
| NCT02375880 | Study of DKN-01 and Gemcitabine/Cisplatin in Patients With Carcinoma to Primary to the Intra- or Extra-Hepatic Biliary System or Gallbladder | completed | Phase 1 | 51 | Leap Therapeutics, Inc.INDUSTRY | 1 | Aug 3, 2025 | clinicaltrials |
| NCT03199586 | Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies | completed | Phase 1 | 23 | Novita Pharmaceuticals, Inc.INDUSTRY | 1 | Jul 20, 2025 | clinicaltrials |
| NCT04242199 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors | completed | Phase 1 | 182 | Incyte CorporationINDUSTRY | 5 | Jul 14, 2025 | clinicaltrials |
| NCT04580485 | INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors | completed | Phase 1 | 54 | Incyte CorporationINDUSTRY | 6 | Jul 11, 2025 | clinicaltrials |
| NCT01628640 | Viral Therapy in Treating Patient With Refractory Liver Cancer or Advanced Solid Tumors | completed | Phase 1 | 17 | Mayo ClinicOTHER | 1 | Jul 3, 2025 | clinicaltrials |
| NCT03781934 | A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations | completed | Phase 1 / Phase 2 | 53 | MedivirINDUSTRY | 4 | Jul 1, 2025 | clinicaltrials |
| NCT05788484 | A Study of CDX-585 in Patients With Advanced Malignancies | completed | Phase 1 | 20 | Celldex TherapeuticsINDUSTRY | 1 | Jun 15, 2025 | clinicaltrials |
| NCT05253053 | To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 84 | TransThera Sciences (Nanjing), Inc.INDUSTRY | 1 | Jun 12, 2025 | clinicaltrials |
| NCT01754987 | A Study of Vitamin C in the Treatment of Liver Cancer to Determine if it is Safe and Effective | completed | Phase 1 / Phase 2 | 5 | Thomas Jefferson UniversityOTHER | 1 | May 4, 2025 | clinicaltrials |
| NCT03045497 | Contrast-Enhanced Ultrasound in Predicting Treatment Response in Patients With Liver Cancer Receiving Transarterial Chemoembolization With Drug Eluting Beads | completed | Phase 1 | 15 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 0 | May 2, 2025 | clinicaltrials |
| NCT02990481 | A Phase 1 Study Evaluating the Safety of TRK-950 in Patients With Advanced Solid Tumors | completed | Phase 1 | 38 | Toray Industries, IncINDUSTRY | 2 | Apr 16, 2025 | clinicaltrials |
| NCT02052778 | A Study of TAS-120 in Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 407 | Taiho Oncology, Inc.INDUSTRY | 13 | Mar 27, 2025 | clinicaltrials |
| NCT04137289 | A Study to Find a Safe and Effective Dose of BI 905711 in Patients With Advanced Gastrointestinal Cancer | completed | Phase 1 | 110 | Boehringer IngelheimINDUSTRY | 8 | Mar 25, 2025 | clinicaltrials |
| NCT03195699 | Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers | completed | Phase 1 | 64 | Tvardi Therapeutics, IncorporatedINDUSTRY | 1 | Mar 21, 2025 | clinicaltrials |
| NCT03397654 | Study of Pembrolizumab Following TACE in Primary Liver Carcinoma(PETAL) | completed | Phase 1 / Phase 2 | 26 | Imperial College LondonOTHER | 1 | Mar 6, 2025 | clinicaltrials |
| NCT03058289 | A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6(IT-01) | completed | Phase 1 / Phase 2 | 111 | Intensity Therapeutics, Inc.INDUSTRY | 2 | Feb 27, 2025 | clinicaltrials |
| NCT02905188 | Glypican 3-specific Chimeric Antigen Receptor Expressing T Cells for Hepatocellular Carcinoma (GLYCAR)(GLYCAR) | completed | Phase 1 | 9 | Baylor College of MedicineOTHER | 1 | Feb 24, 2025 | clinicaltrials |
| NCT03190174 | Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers | completed | Phase 1 / Phase 2 | 34 | Sarcoma Oncology Research Center, LLCOTHER | 1 | Feb 17, 2025 | clinicaltrials |
| NCT02421185 | Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 (Erdafitinib) in Participants With Advanced Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 53 | Janssen Research & Development, LLCINDUSTRY | 3 | Feb 3, 2025 | clinicaltrials |
Data updated yesterdaySource updated Sep 29, 2026source: clinicaltrials